SCHEMBL10102630

SCHEMBL10102630

N#Cc1ccc2nc(-c3ccccc3)c(CCCO)cc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.38
ATM Q13315 1/20 0.38
ADORA2A P29274 4/20 0.38
ADORA1 P30542 3/20 0.38
ALDH1A1 P00352 4/20 0.37
KDM4E B2RXH2 3/20 0.37
CYP19A1 P11511 2/20 0.37
LMNA P02545 2/20 0.37
HTT P42858 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
THRB P10828 1/20 0.37
CSNK1A1 P48729 1/20 0.37
CSNK1D P48730 1/20 0.37
GSK3B P49841 1/20 0.37
CSNK1G2 P78368 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.36
ADORA2B P29275 2/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
PSMB5 P28074 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10102645 0.80 CNR2 (0.38) KMT2AADORA2AADORA1ALDH1A1CSNK1A1
SCHEMBL10102646 0.80 CTSK (0.47) ADORA2AADORA1PTGDR2ADORA2BCFTR
SCHEMBL10102628 0.79 DHODH (0.46) KMT2AATMALDH1A1KDM4ELMNA
SCHEMBL10102670 0.79 PSMB5 (0.47) KMT2AATMALDH1A1KDM4EPSMB5
SCHEMBL13005210 0.78 AKT1 (0.39) KMT2AATMALDH1A1KDM4EPSMB5
SCHEMBL10102635 0.78 PSMB5 (0.39) KMT2AATMALDH1A1KDM4ELMNA
SCHEMBL3383001 0.78 DHODH (0.45) KMT2AATMKDM4E
SCHEMBL10102632 0.75 DHFR (0.41) KMT2AATMPTGDR2CYP11B1CYP11B2
SCHEMBL4915121 0.72 PDE10A (0.53) KMT2AALDH1A1KDM4ELMNAHTT
SCHEMBL3386971 0.72 KDM4E (0.54) KMT2AALDH1A1KDM4ELMNAPSMB5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207345-B2 Antitumor agents; use in combination with other drugs such as pentamidine MERCK PATENT GMBH (DE) 2012-06-26 US disclosed
US-8207345-B2 Antitumor agents; use in combination with other drugs such as pentamidine MERCK PATENT GMBH (DE) 2012-06-26 US disclosed
EP-1891011-B1 TETRAHYDROQUINOLINES USED IN THE FORM OF MODULATORS OF MITOTIC MOTOR-PROTEINS EG5 MERCK PATENT GMBH (DE) 2010-12-08 EP disclosed
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 MERCK PATENT GMBH (DE) 2008-08-21 US disclosed
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 MERCK PATENT GMBH (DE) 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 KIF5A, KIF5C, KIF5B KMT2A 1558/4885ATM 2710/4885ADORA2A 4792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.